Jane Henney impresses during FDA Commissioner hearings but appointment may be delayed until next year
This article was originally published in Clinica
From her management style to such controversial topics as off-label use and pre-emption, there was much for the device industry to like in what Jane Henney, the Clinton administration candidate for FDA Commissioner, had to say at her confirmation hearing last week.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.